Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 174.97 Billion KRW | 11.2% |
| 2022 | 157.35 Billion KRW | 29.49% |
| 2021 | 121.52 Billion KRW | 54.99% |
| 2020 | 78.4 Billion KRW | 1.94% |
| 2019 | 76.91 Billion KRW | 20.71% |
| 2018 | 63.71 Billion KRW | 5.83% |
| 2017 | 60.2 Billion KRW | 150.53% |
| 2016 | 24.03 Billion KRW | -3.05% |
| 2015 | 24.78 Billion KRW | -29.0% |
| 2014 | 34.91 Billion KRW | 1224.23% |
| 2013 | 2.63 Billion KRW | -84.12% |
| 2012 | 16.6 Billion KRW | -46.7% |
| 2011 | 31.15 Billion KRW | -16.62% |
| 2010 | 37.36 Billion KRW | 20.15% |
| 2009 | 31.1 Billion KRW | 17.79% |
| 2008 | 26.4 Billion KRW | 3852.15% |
| 2007 | -703.71 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 140.53 Billion KRW | -9.1% |
| 2024 Q1 | 154.6 Billion KRW | -11.64% |
| 2023 FY | 174.97 Billion KRW | 11.2% |
| 2023 Q1 | 156.73 Billion KRW | -0.39% |
| 2023 Q4 | 174.97 Billion KRW | -0.28% |
| 2023 Q3 | 175.46 Billion KRW | 6.78% |
| 2023 Q2 | 164.31 Billion KRW | 4.84% |
| 2022 Q2 | 138.16 Billion KRW | 12.68% |
| 2022 Q4 | 157.35 Billion KRW | 0.26% |
| 2022 Q3 | 156.95 Billion KRW | 13.6% |
| 2022 Q1 | 122.61 Billion KRW | 0.9% |
| 2022 FY | 157.35 Billion KRW | 29.49% |
| 2021 Q3 | 106.63 Billion KRW | 0.6% |
| 2021 FY | 121.52 Billion KRW | 54.99% |
| 2021 Q4 | 121.52 Billion KRW | 13.97% |
| 2021 Q1 | 87.2 Billion KRW | 11.22% |
| 2021 Q2 | 105.99 Billion KRW | 21.54% |
| 2020 Q4 | 78.4 Billion KRW | -6.84% |
| 2020 Q1 | 74.69 Billion KRW | -2.88% |
| 2020 Q2 | 83.87 Billion KRW | 12.29% |
| 2020 Q3 | 84.16 Billion KRW | 0.34% |
| 2020 FY | 78.4 Billion KRW | 1.94% |
| 2019 FY | 76.91 Billion KRW | 20.71% |
| 2019 Q4 | 76.91 Billion KRW | 48.06% |
| 2019 Q2 | 62.12 Billion KRW | 4.7% |
| 2019 Q1 | 59.34 Billion KRW | -6.87% |
| 2019 Q3 | 51.94 Billion KRW | -16.39% |
| 2018 Q3 | 61.5 Billion KRW | -6.45% |
| 2018 FY | 63.71 Billion KRW | 5.83% |
| 2018 Q1 | 64.06 Billion KRW | 6.41% |
| 2018 Q2 | 65.74 Billion KRW | 2.62% |
| 2018 Q4 | 63.71 Billion KRW | 3.6% |
| 2017 Q3 | 57.93 Billion KRW | 4.09% |
| 2017 FY | 60.2 Billion KRW | 150.53% |
| 2017 Q1 | 26.17 Billion KRW | 8.93% |
| 2017 Q4 | 60.2 Billion KRW | 3.93% |
| 2017 Q2 | 55.65 Billion KRW | 112.6% |
| 2016 FY | 24.03 Billion KRW | -3.05% |
| 2016 Q4 | 24.03 Billion KRW | 10.86% |
| 2016 Q3 | 21.67 Billion KRW | -4.65% |
| 2016 Q2 | 22.73 Billion KRW | -14.26% |
| 2016 Q1 | 26.51 Billion KRW | 6.98% |
| 2015 Q3 | 26.85 Billion KRW | 6.74% |
| 2015 Q1 | 30.25 Billion KRW | -13.34% |
| 2015 Q2 | 25.15 Billion KRW | -16.87% |
| 2015 FY | 24.78 Billion KRW | -29.0% |
| 2015 Q4 | 24.78 Billion KRW | -7.68% |
| 2014 Q2 | 26.2 Billion KRW | 61.8% |
| 2014 Q1 | 16.19 Billion KRW | 514.34% |
| 2014 FY | 34.91 Billion KRW | 1224.23% |
| 2014 Q4 | 34.91 Billion KRW | 6.85% |
| 2014 Q3 | 32.67 Billion KRW | 24.68% |
| 2013 Q1 | 18.94 Billion KRW | 14.07% |
| 2013 FY | 2.63 Billion KRW | -84.12% |
| 2013 Q3 | 18.75 Billion KRW | -4.8% |
| 2013 Q2 | 19.7 Billion KRW | 4.03% |
| 2013 Q4 | 2.63 Billion KRW | -85.94% |
| 2012 Q4 | 16.6 Billion KRW | 0.0% |
| 2012 FY | 16.6 Billion KRW | -46.7% |
| 2012 Q1 | 29.06 Billion KRW | 0.0% |
| 2011 Q2 | 35.48 Billion KRW | 7.94% |
| 2011 Q3 | 33.03 Billion KRW | -6.91% |
| 2011 FY | 31.15 Billion KRW | -16.62% |
| 2011 Q1 | 32.87 Billion KRW | -12.02% |
| 2010 Q2 | 28.27 Billion KRW | 48.21% |
| 2010 FY | 37.36 Billion KRW | 20.15% |
| 2010 Q1 | 19.07 Billion KRW | -38.65% |
| 2010 Q4 | 37.36 Billion KRW | 21.03% |
| 2010 Q3 | 30.87 Billion KRW | 9.18% |
| 2009 Q2 | 31.5 Billion KRW | 16.67% |
| 2009 Q3 | 29.97 Billion KRW | -4.87% |
| 2009 Q1 | 27 Billion KRW | 2.27% |
| 2009 FY | 31.1 Billion KRW | 17.79% |
| 2009 Q4 | 31.1 Billion KRW | 3.76% |
| 2008 FY | 26.4 Billion KRW | 3852.15% |
| 2008 Q2 | 18.73 Billion KRW | 65.85% |
| 2008 Q4 | 26.4 Billion KRW | 1.79% |
| 2008 Q3 | 25.94 Billion KRW | 38.43% |
| 2008 Q1 | 11.29 Billion KRW | 1705.71% |
| 2007 Q3 | -2.17 Billion KRW | 26.06% |
| 2007 Q4 | -703.71 Million KRW | 67.57% |
| 2007 FY | -703.71 Million KRW | 0.0% |
| 2007 Q1 | -6.28 Billion KRW | 0.0% |
| 2007 Q2 | -2.93 Billion KRW | 53.34% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1887.817% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 69.412% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 43.716% |
| HANDOK Inc. | 283.45 Billion KRW | 38.271% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -771.717% |
| Yuhan Corporation | -69.18 Billion KRW | 352.9% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 9.785% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 4847.191% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 66.214% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 639.508% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -131.217% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -374.987% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -112.036% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -596.869% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1887.817% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 209.462% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 12.926% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -2.357% |
| JW Holdings Corporation | 480.68 Billion KRW | 63.6% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -6.313% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -148773.055% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -13.345% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7341.469% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -660.703% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -236.65% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1887.817% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -10.535% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 51.149% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -13.345% |
| Yuhan Corporation | -69.18 Billion KRW | 352.9% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -28.664% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -193.213% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 59.228% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -13.345% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -50.531% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -965.276% |
| CKD Bio Corp. | 143.29 Billion KRW | -22.106% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -50.751% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 827.183% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 491.139% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7341.469% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 58.62% |
| Boryung Corporation | 187.72 Billion KRW | 6.795% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 343.558% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -131.217% |
| JW Lifescience Corporation | 26.09 Billion KRW | -570.632% |